These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34889100)

  • 1. Recent Advances in the Medicinal Chemistry of Farnesoid X Receptor.
    Fang Y; Hegazy L; Finck BN; Elgendy B
    J Med Chem; 2021 Dec; 64(24):17545-17571. PubMed ID: 34889100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patented Farnesoid X receptor modulators: a review (2019 - present).
    Gioiello A; Rosatelli E; Cerra B
    Expert Opin Ther Pat; 2024 Jul; 34(7):547-564. PubMed ID: 38308658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
    Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
    Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesoid X receptor: from medicinal chemistry to clinical applications.
    Fiorucci S; Mencarelli A; Distrutti E; Zampella A
    Future Med Chem; 2012 May; 4(7):877-91. PubMed ID: 22571613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Farnesoid X receptor modulators 2014-present: a patent review.
    Sepe V; Distrutti E; Fiorucci S; Zampella A
    Expert Opin Ther Pat; 2018 May; 28(5):351-364. PubMed ID: 29649907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural Products in the Modulation of Farnesoid X Receptor Against Nonalcoholic Fatty Liver Disease.
    Wang J; Yang N; Xu Y
    Am J Chin Med; 2024; 52(2):291-314. PubMed ID: 38480498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis.
    Cariou B
    Diabetes Metab; 2008 Dec; 34(6 Pt 2):685-91. PubMed ID: 19195631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators.
    Merk D; Steinhilber D; Schubert-Zsilavecz M
    Future Med Chem; 2012 May; 4(8):1015-36. PubMed ID: 22650242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist.
    Merk D; Lamers C; Ahmad K; Carrasco Gomez R; Schneider G; Steinhilber D; Schubert-Zsilavecz M
    J Med Chem; 2014 Oct; 57(19):8035-55. PubMed ID: 25255039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FXR modulators for enterohepatic and metabolic diseases.
    Wang H; He Q; Wang G; Xu X; Hao H
    Expert Opin Ther Pat; 2018 Nov; 28(11):765-782. PubMed ID: 30259754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesoid X Receptor as a Promising Therapeutic Target for Nonalcoholic Fatty Liver Disease (NAFLD) and the Current Development of Its Agonists.
    Shen T; Shi A; Wei Y; Luo X; Xi L
    Discov Med; 2021; 32(167):113-121. PubMed ID: 35220997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemistry and Pharmacology of GPBAR1 and FXR Selective Agonists, Dual Agonists, and Antagonists.
    De Marino S; Festa C; Sepe V; Zampella A
    Handb Exp Pharmacol; 2019; 256():137-165. PubMed ID: 31201554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FXR: structures, biology, and drug development for NASH and fibrosis diseases.
    Tian SY; Chen SM; Pan CX; Li Y
    Acta Pharmacol Sin; 2022 May; 43(5):1120-1132. PubMed ID: 35217809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease.
    Xi Y; Li H
    Biomed Pharmacother; 2020 Jan; 121():109609. PubMed ID: 31731192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bile acid derivatives as ligands of the farnesoid x receptor: molecular determinants for bile acid binding and receptor modulation.
    Gioiello A; Cerra B; Mostarda S; Guercini C; Pellicciari R; Macchiarulo A
    Curr Top Med Chem; 2014; 14(19):2159-74. PubMed ID: 25388535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 4-aminophenylacetamide derivatives as intestine-specific farnesoid X receptor antagonists for the potential treatment of nonalcoholic steatohepatitis.
    Chen C; Zhang B; Tu J; Peng Y; Zhou Y; Yang X; Yu Q; Tan X
    Eur J Med Chem; 2024 Jan; 264():115992. PubMed ID: 38043493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.
    Li J; Liu M; Li Y; Sun DD; Shu Z; Tan Q; Guo S; Xie R; Gao L; Ru H; Zang Y; Liu H; Li J; Zhou Y
    J Med Chem; 2020 Nov; 63(21):12748-12772. PubMed ID: 32991173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel ketoxime ether derivatives with potent FXR agonistic activity, oral effectiveness and high liver/blood ratio.
    Tang X; Ning M; Ye Y; Gu Y; Yan H; Leng Y; Shen J
    Bioorg Med Chem; 2021 Aug; 43():116280. PubMed ID: 34256254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond bile acids: targeting Farnesoid X Receptor (FXR) with natural and synthetic ligands.
    Carotti A; Marinozzi M; Custodi C; Cerra B; Pellicciari R; Gioiello A; Macchiarulo A
    Curr Top Med Chem; 2014; 14(19):2129-42. PubMed ID: 25388537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
    Zhang C; Liu Y; Wang Y; Ge X; Jiao T; Yin J; Wang K; Li C; Guo S; Xie X; Xie C; Nan F
    J Med Chem; 2022 Oct; 65(19):13452-13472. PubMed ID: 36107013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.